Phase I/II study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer

European Journal of Cancer

Volumn 45, Issue 12, 2009, Pages 2132-2137

  Tamura, Kenji ^a,b   Okamoto, Isamu ^b   Ozaki, Tomohiro ^c   Kashii, Tatsuhiko ^d   Takeda, Koji ^d   Kobayashi, Masashi ^e   Matsui, Kaoru ^e   Shibata, Takashi ^a   Kurata, Takayasu ^f   Nakagawa, Kazuhiko ^b   Fukuoka, Masahiro ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KINDAI UNIVERSITY NARA HOSPITAL   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^f OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Carboplatin; Chemotherapy; Non small cell lung cancer (NSCLC); Phase I II study; S 1

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CARBOPLATIN; CREATININE;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTRITIS; HUMAN; INFECTION; LARGE CELL CARCINOMA; LEUKOPENIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PLEURISY; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SIDE EFFECT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DRUG COMBINATIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; OXONIC ACID; TEGAFUR;

EID: 67650935590     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.04.003     Document Type: Article

References (20)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Kubota K., Watanabe K., Kunitoh H., et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 22 (2004) 254-261
3. Le Chevalier T., Brisgand D., Douillard J.Y., et al. Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12 (1994) 360-368
4. Cardenal F., López-Cabrerizo M.P., Antón A., et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 17 (1999) 12-18
5. Schiller J.H., Harrington D., Belani C.P., et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346 (2002) 92-98
6. Shirasaka T., Shimamoto Y., Ohshimo H., et al. Department of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7 (1996) 548-557
7. Takechi T., Fujioka A., Matsushima E., and Fukushima M. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2, 4-dihydroxypyridine (CDHP) in human tumour cells. Eur J Cancer 38 (2002) 1271-1277
8. Takechi T., Nakano K., Uchida J., et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39 (1997) 205-211
9. Kawahara M., Furuse K., Segawa Y., et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85 (2001) 939-943
10. Ichinose Y., Yoshimori K., Sakai H., et al. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional phase II trial. Clin Cancer Res 10 (2004) 7860-7864
11. Calvert A.H., Newell D.R., Gumbrell L.A., et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7 (1989) 1748-1756
12. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
13. Hotta K., Matsuo K., Ueoka H., et al. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22 (2004) 3852-3859
14. Socinski M.A., Crowell R., Hensing T.E., et al. Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 Suppl. 3 (2007) 277S-289S
15. Weiss R.B., Donehower R.C., Wiernik P.H., et al. Hypersensitivity reactions from taxol. J Clin Oncol 8 (1990) 1263-1268
16. Shirasaka T., Shimamoto Y., Ohshimo H., et al. Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer Chemother Pharmacol 32 (1993) 167-172
17. Sakaki E., Tominaga K., Kuwamura H., et al. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2, 4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism. J Gastroenterol 4 (2007) 816-822
18. Koizumi W., Narahara H., Hara T., et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9 (2008) 215-221
19. Kaira K., Sunaga N., Yanagitani N., et al. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. Anticancer Drugs 18 (2007) 471-476
20. Ohe Y., Ohashi Y., Kubota K., et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18 (2007) 317-323